Targeted Therapy
Approved for: NSCLC
Biomarker: EGFR exon 20
The FDA has approved amivantamab-vmjw (Rybrevant) as the first treatment for adult patients with non–small cell lung cancer (NSCLC) who harbor EGFR exon 20 insertion mutations.
FDA-Approved Lung Cancer Treatments
Amivantamab (Rybrevant)
I want to give in honor of...
name or relation
Donation Amount
other amount